Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Maternal folic acid supplementation does not counteract the deleterious impact of prenatal exposure to environmental pollutants on lipid homeostasis in male rat descendants.

Navarro P, Dalvai M, Charest PL, Herst PM, Lessard M, Marcotte B, Mitchell PL, Leblanc N, Kimmins S, Trasler J, MacFarlane AJ, Marette A, Bailey JL, Jacques H.

J Dev Orig Health Dis. 2019 Sep 16:1-11. doi: 10.1017/S2040174419000497. [Epub ahead of print]

PMID:
31525320
2.

The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis.

Mouchiroud M, Camiré É, Aldow M, Caron A, Jubinville É, Turcotte L, Kaci I, Beaulieu MJ, Roy C, Labbé SM, Varin TV, Gélinas Y, Lamothe J, Trottier J, Mitchell PL, Guénard F, Festuccia WT, Joubert P, Rose CF, Karvellas CJ, Barbier O, Morissette MC, Marette A, Laplante M.

JCI Insight. 2019 Aug 8;4(15). pii: 129492. doi: 10.1172/jci.insight.129492. eCollection 2019 Aug 8.

3.

Acute and chronic effect of bariatric surgery on circulating autotaxin levels.

Bourgeois R, Piché ME, Auclair A, Grenier-Larouche T, Mitchell PL, Poirier P, Biertho L, Marceau S, Hould FS, Biron S, Lebel S, Lescelleur O, Julien F, Martin J, Tchernof A, Mathieu P, Carpentier AC, Arsenault BJ.

Physiol Rep. 2019 Mar;7(5):e14004. doi: 10.14814/phy2.14004.

4.

Correction to: Differences in cancer survival by sex: a population-based study using cancer registry data.

Afshar N, English DR, Thursfield V, Mitchell PL, Te Marvelde L, Farrugia H, Giles GG, Milne RL.

Cancer Causes Control. 2018 Nov;29(11):1071. doi: 10.1007/s10552-018-1089-x.

PMID:
30311110
5.

Differences in cancer survival by sex: a population-based study using cancer registry data.

Afshar N, English DR, Thursfield V, Mitchell PL, Te Marvelde L, Farrugia H, Giles GG, Milne RL.

Cancer Causes Control. 2018 Nov;29(11):1059-1069. doi: 10.1007/s10552-018-1079-z. Epub 2018 Sep 7. Erratum in: Cancer Causes Control. 2018 Oct 11;:.

PMID:
30194549
6.

Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia.

Boyer M, Mitchell PL, Poirier P, Alméras N, Tremblay A, Bergeron J, Després JP, Arsenault BJ.

Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E460-E468. doi: 10.1152/ajpendo.00127.2018. Epub 2018 Jun 5.

7.

Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy.

Boyer M, Lévesque V, Poirier P, Marette A, Mitchell PL, Mora S, Mathieu P, Després JP, Larose É, Arsenault BJ.

J Am Heart Assoc. 2018 Jun 1;7(11). pii: e008681. doi: 10.1161/JAHA.118.008681.

8.

Lung cancer in Asian women and health system implications for Australia.

Emery JD, Mitchell PL.

Lancet Oncol. 2017 Dec;18(12):1570-1571. doi: 10.1016/S1470-2045(17)30853-7. No abstract available.

PMID:
29208428
9.

Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase.

Do H, Molania R, Mitchell PL, Vaiskunaite R, Murdoch JD, Dobrovic A.

Clin Chem. 2017 Sep;63(9):1506-1514. doi: 10.1373/clinchem.2017.271932. Epub 2017 Jul 18.

10.

Lung cancer in 2016: immunotherapy comes of age.

Mitchell PL, John T.

Lancet Respir Med. 2016 Dec;4(12):947-949. doi: 10.1016/S2213-2600(16)30379-4. Epub 2016 Nov 22. No abstract available.

PMID:
27890503
11.

Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.

Mitchell PL, Nachbar R, Lachance D, St-Pierre P, Trottier J, Barbier O, Marette A.

Diabetes Obes Metab. 2017 Mar;19(3):313-319. doi: 10.1111/dom.12818. Epub 2016 Dec 9.

PMID:
27800648
12.

Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.

Do H, Cameron D, Molania R, Thapa B, Rivalland G, Mitchell PL, Murone C, John T, Papenfuss A, Dobrovic A.

Adv Exp Med Biol. 2016;924:139-146.

PMID:
27753035
13.

Low-Molecular-Weight Peptides from Salmon Protein Prevent Obesity-Linked Glucose Intolerance, Inflammation, and Dyslipidemia in LDLR-/-/ApoB100/100 Mice.

Chevrier G, Mitchell PL, Rioux LE, Hasan F, Jin T, Roblet CR, Doyen A, Pilon G, St-Pierre P, Lavigne C, Bazinet L, Jacques H, Gill T, McLeod RS, Marette A.

J Nutr. 2015 Jul;145(7):1415-22. doi: 10.3945/jn.114.208215. Epub 2015 May 20.

PMID:
25995281
14.

Transgenic ω-3 PUFA enrichment alters morphology and gene expression profile in adipose tissue of obese mice: Potential role for protectins.

White PJ, Mitchell PL, Schwab M, Trottier J, Kang JX, Barbier O, Marette A.

Metabolism. 2015 Jun;64(6):666-76. doi: 10.1016/j.metabol.2015.01.017. Epub 2015 Feb 3. Erratum in: Metabolism. 2015 Sep;64(9):e7-8.

PMID:
25726444
15.

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.

Mitchell PL, Quinn MA, Grant PT, Allen DG, Jobling TW, White SC, Zhao A, Karanikas V, Vaughan H, Pietersz G, McKenzie IF, Gargosky SE, Loveland BE.

J Immunother Cancer. 2014 Jun 18;2:16. doi: 10.1186/2051-1426-2-16. eCollection 2014.

16.

Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis.

White PJ, St-Pierre P, Charbonneau A, Mitchell PL, St-Amand E, Marcotte B, Marette A.

Nat Med. 2014 Jun;20(6):664-9. doi: 10.1038/nm.3549. Epub 2014 May 11.

17.

A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.

Do H, Wong NC, Murone C, John T, Solomon B, Mitchell PL, Dobrovic A.

Sci Rep. 2014 Feb 26;4:4186. doi: 10.1038/srep04186.

18.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team.

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

19.

Lung cancer in Victoria: are we making progress?

Mitchell PL, Thursfield VJ, Ball DL, Richardson GE, Irving LB, Torn-Broers Y, Giles GG, Wright GM.

Med J Aust. 2013 Nov 18;199(10):674-9.

PMID:
24237097
20.

Should we screen for lung cancer in Australia?

Mitchell PL, John T.

Med J Aust. 2013 Nov 4;199(9):586. No abstract available.

PMID:
24182221
21.

Anti-diabetic and antihypertensive activities of two flaxseed protein hydrolysate fractions revealed following their simultaneous separation by electrodialysis with ultrafiltration membranes.

Doyen A, Udenigwe CC, Mitchell PL, Marette A, Aluko RE, Bazinet L.

Food Chem. 2014 Feb 15;145:66-76. doi: 10.1016/j.foodchem.2013.07.108. Epub 2013 Jul 29.

PMID:
24128450
22.

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS.

PLoS One. 2013 Jul 23;8(7):e67876. doi: 10.1371/journal.pone.0067876. Print 2013.

23.

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.

Lester JF, Agulnik J, Akerborg O, Chouaid C, De Geer A, Finnern HW, Herder GJ, Lungershausen J, Mitchell PL, Vansteenkiste J, Ziske C, Goker E.

Lung Cancer. 2013 Oct;82(1):128-35. doi: 10.1016/j.lungcan.2013.06.023. Epub 2013 Jul 31.

PMID:
23910909
24.

Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting.

Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, Finnern HW, Lungershausen J, Eriksson J, Kim K, Mitchell PL.

J Thorac Oncol. 2013 Aug;8(8):997-1003. doi: 10.1097/JTO.0b013e318299243b.

25.

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.

Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PLR, Pavlakis N, Boyer M, Stockler MR.

Lung Cancer. 2013 Sep;81(3):422-427. doi: 10.1016/j.lungcan.2013.05.006. Epub 2013 Jun 17.

PMID:
23787063
26.

t-10, c-12 CLA dietary supplementation inhibits atherosclerotic lesion development despite adverse cardiovascular and hepatic metabolic marker profiles.

Mitchell PL, Karakach TK, Currie DL, McLeod RS.

PLoS One. 2012;7(12):e52634. doi: 10.1371/journal.pone.0052634. Epub 2012 Dec 20.

27.

Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies.

Scott AM, Mitchell PL, O'Keefe G, Saunder T, Hicks RJ, Poon A, Baum C, Brega N, McCarthy TJ, Toner GC.

EJNMMI Res. 2012 Jun 9;2(1):31. doi: 10.1186/2191-219X-2-31.

28.

Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer.

Mitchell PL, Broad A, Rosenthal MA, Galettis P, Abraham R, Burns I, Clarke S, Milner A, Diiulio J, Links M.

Asia Pac J Clin Oncol. 2011 Dec;7(4):376-84. doi: 10.1111/j.1743-7563.2011.01390.x. Epub 2011 May 23.

PMID:
22151988
29.

Conjugated linoleic acid supplementation for 8 weeks does not affect body composition, lipid profile, or safety biomarkers in overweight, hyperlipidemic men.

Joseph SV, Jacques H, Plourde M, Mitchell PL, McLeod RS, Jones PJ.

J Nutr. 2011 Jul;141(7):1286-91. doi: 10.3945/jn.110.135087. Epub 2011 May 18.

PMID:
21593349
30.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

31.

Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.

Do H, Salemi R, Murone C, Mitchell PL, Dobrovic A.

Cell Cycle. 2010 Nov 1;9(21):4411-2. Epub 2010 Nov 13. No abstract available.

PMID:
20980808
32.

Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.

Gan HK, Azad A, Cher L, Mitchell PL.

Neuro Oncol. 2010 Feb;12(2):212-5. doi: 10.1093/neuonc/nop021. Epub 2009 Dec 24.

33.

High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.

Azad A, Chionh F, Scott AM, Lee ST, Berlangieri SU, White S, Mitchell PL.

Mol Imaging Biol. 2010 Aug;12(4):443-51. doi: 10.1007/s11307-009-0295-z. Epub 2009 Nov 17.

PMID:
19921339
34.

Orienting of visual attention among persons with autism spectrum disorders: reading versus responding to symbolic cues.

Landry O, Mitchell PL, Burack JA.

J Child Psychol Psychiatry. 2009 Jul;50(7):862-70. doi: 10.1111/j.1469-7610.2008.02049.x.

PMID:
19527316
35.

Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.

Azad A, Herbertson RA, Pook D, White S, Mitchell PL, Tebbutt NC.

Acta Oncol. 2009;48(4):619-21. doi: 10.1080/02841860802495362. No abstract available.

PMID:
18979266
36.

Conjugated linoleic acid and atherosclerosis: studies in animal models.

Mitchell PL, McLeod RS.

Biochem Cell Biol. 2008 Aug;86(4):293-301. doi: 10.1139/o08-070. Review.

PMID:
18756324
37.

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting.

Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A.

BMC Res Notes. 2008 May 16;1:14. doi: 10.1186/1756-0500-1-14.

38.

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.

Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A.

BMC Cancer. 2008 May 21;8:142. doi: 10.1186/1471-2407-8-142.

39.

A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.

Mitchell PL, Marlton P, Grigg A, Seymour JF, Hertzberg M, Enno A, Herrmann R, Bond R, Arthur C.

Leuk Lymphoma. 2008 May;49(5):924-31. doi: 10.1080/10428190802007700.

PMID:
18464112
40.

Systems biology or the biology of systems: routes to reducing hunger.

Sheehy JE, Gunawardana D, Ferrer AB, Danila F, Tan KG, Mitchell PL.

New Phytol. 2008;179(3):579-82. doi: 10.1111/j.1469-8137.2008.02407.x. Epub 2008 Mar 4. No abstract available.

41.

Conjugated linoleic acid isomers have no effect on atherosclerosis and adverse effects on lipoprotein and liver lipid metabolism in apoE-/- mice fed a high-cholesterol diet.

Cooper MH, Miller JR, Mitchell PL, Currie DL, McLeod RS.

Atherosclerosis. 2008 Oct;200(2):294-302. doi: 10.1016/j.atherosclerosis.2007.12.040. Epub 2008 Feb 15.

PMID:
18280484
42.

Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.

Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ.

Br J Clin Pharmacol. 2008 Mar;65(3):326-33. Epub 2007 Oct 24.

43.

Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.

Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S.

Clin Colorectal Cancer. 2006 Jul;6(2):146-51.

PMID:
16945171
44.

Supercharging rice photosynthesis to increase yield.

Mitchell PL, Sheehy JE.

New Phytol. 2006;171(4):688-93. No abstract available.

45.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR.

J Clin Oncol. 2006 Sep 10;24(26):4228-35. Epub 2006 Aug 8.

PMID:
16896007
46.

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77.

47.

A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.

Gan HK, Mitchell PL, Galettis P, Davis ID, Cebon J, de Souza P, Links M.

Cancer Chemother Pharmacol. 2006 Aug;58(2):157-64. Epub 2005 Nov 19.

PMID:
16328413
48.

Effect of conjugated linoleic acid isomers on lipoproteins and atherosclerosis in the Syrian Golden hamster.

Mitchell PL, Langille MA, Currie DL, McLeod RS.

Biochim Biophys Acta. 2005 Jun 1;1734(3):269-76.

PMID:
15919237
49.

Bi-phasic growth patterns in rice.

Sheehy JE, Mitchell PL, Ferrer AB.

Ann Bot. 2004 Dec;94(6):811-7. Epub 2004 Oct 5.

Supplemental Content

Loading ...
Support Center